There is increased consumer awareness that foods contain microcomponents that may have beneficial effects on health maintenance and disease prevention. In milk fat these functional food components include EPA, DHA, and CLA. The opportunity to enhance the content of these FA in milk has improved as a result of recent advances that have better defined the interrelationships between rumen fermentation, lipid metabolism, and milk fat synthesis. Dietary lipids undergo extensive hydrolysis and biohydrogenation in the rumen. Milk fat is predominantly TG, and de novo FA synthesis and the uptake of circulating FA contribute nearly equal amounts (molar basis) to the FA in milk fat. Transfer of dietary EPA and DHA to milk fat is very low (<4%); this is, to a large extent, related to their extensive biohydrogenation in the rumen, and also partly due to the fact that they are not transported in the plasma lipid fractions that serve as major mammary sources of FA uptake (TG and nonesterified FA). Milk contains over 20 isomers of CLA but the predominant one is cis-9,trans-11 (75-90% of total CLA). Biomedical studies with animal models have shown that this isomer has anticarcinogenic and anti-atherogenic activities. cis-9,trans-11-CLA is produced as an intermediate in the rumen biohydrogenation of linoleic acid but not of linolenic acid. However, it is only a transient intermediate, and the major source of milk fat CLA is from endogenous synthesis. Vaccenic acid, produced as a rumen biohydrogenation intermediate from both linoleic acid and linolenic acid, is the substrate, and ∆9-desaturase in the mammary gland and other tissues catalyzes the reaction. Diet can markedly affect milk fat CLA content, and there are also substantial differences among individual cows. Thus, strategies to enhance milk fat CLA involve increasing rumen outflow of vaccenic acid and increasing ∆9-desaturase activity, and through these, several-fold increases in the content of CLA in milk fat can be routinely achieved. Overall, concentrations of CLA, and to a lesser extent EPA and DHA, can be significantly enhanced through the use of diet formulation and nutritional management of dairy cows.
Historically, the goal of agricultural research has been to increase yield and productive efficiency, with little focus given to improving the nutrient profile of food products. Mounting research evidence and consumer awareness of the potential health benefits of various microcomponents in foods has given rise to the concept of functional foods and helped create a demand for foods with improved nutrient profiles (1) . Thus, producers and scientists are interested in research and agricultural practices that may improve the nutrient profile of food products (2) . One such example is the dairy industry and recent efforts to modify the composition of milk fat.
Milk and dairy products are recognized as important sources of nutrients in human diets, providing energy, high quality protein, and essential minerals and vitamins (3, 4) . Milk fat is responsible for many of the sensory, physical, and manufacturing properties of dairy products (5) . However, milk fat is relatively more saturated than most plant oils, and this has led to a negative consumer perception and a public health concern related to excessive intake of saturated fats.
Milk fat content and FA composition can be significantly altered through nutrition of the dairy cows, offering the opportunity to respond to market forces and human health recommendations (6) . The impact of dairy cow nutrition on fat content and FA composition of milk has been extensively reviewed (6) (7) (8) (9) (10) (11) (12) . Due to increased consumer awareness of the link between diet and health, research has focused on altering the FA composition of cows' milk to achieve a FA profile consistent with consumer perceptions and health recommendations. In the past, much of this work has involved studies in which whole-scale changes have been the goal, whereby large shifts in the saturated to PUFA ratio have been sought. Modest changes have been achievable, but this can lead to problems relating to product quality and stability.
Recent research has demonstrated that generalizations about fat and FA are of little value and often lead to misleading and erroneous public understanding. Instead, one must consider the biological effects and nutritional value on the basis of individual FA. The focus of this review is on the nutritional manipulation of omega-3 FA and CLA, and possible constraints to their enhancement in milk and dairy products. These FA are of particular interest because of their potential benefits to human health. However, modification of the FA content of milk fat in dairy cows is impacted significantly by the extensive metabolism of lipids that occurs in the rumen. Hence, we will also provide a brief background on lipid metabolism in the rumen and milk fat synthesis.
Analytical developments that improved our ability to quantify the intermediates of FA metabolism have played a major role in these advances. Diets consumed by lactating dairy cows are low in fat content, generally containing only about 4-5% lipid. The predominant PUFA in ruminant diets are linolenic acid and linoleic acid, the former derived principally from forage crops and the latter being a major component of the oilseeds and concentrates that are fed to dairy cows.
The rumen of a dairy cow has a 40-to 50-L fluid volume with 10 10 to 10 11 bacteria and 10 5 to 10 6 protozoa per milliliter of rumen contents. When dietary lipids enter the rumen, the initial step in lipid metabolism is the hydrolysis of the ester linkages found in TG, phospholipids, and glycolipids, and this is primarily carried out by hydrolases produced by rumen bacteria. The extent of hydrolysis is generally high (>85%), and a number of factors that affect the rate and extent of hydrolysis have been identified [see reviews by Doreau and Ferlay (13), Doreau and Chilliard (14) , and Harfoot and Hazlewood (15) ].
Biohydrogenation of unsaturated FA is the second major transformation that dietary lipids undergo in the rumen, and it requires an FFA to proceed. As a consequence, rates are always lower than those for hydrolysis, and factors that affect hydrolysis also affect biohydrogenation. In addition, the rate of rumen biohydrogenation of FA typically increases as the extent of unsaturation in the FA increases (16) . Biohydrogenation involves only a few of the species of rumen bacteria, and they carry out these reactions as a protection mechanism against the toxic effects of PUFA. Biohydrogenation is extensive, and for most diets linoleic and linolenic acid are hydrogenated 70-95% and 85-100%, respectively (13) (14) (15) 17) . Classical pathways of biohydrogenation were established using pure cultures of rumen organisms (Fig. 1 ). Based on their metabolic pathways, the bacteria involved in biohydrogenation have been classified into two groups: Group A bacteria hydrogenate PUFA to trans 18:1 FA, and Group B bacteria hydrogenate the trans 18:1 FA to stearic acid (15) . Thus, in general no single species catalyzes the full sequence of reactions to convert linoleic and linolenic acid to stearic acid (18) . For a more indepth review of rumen bacteria and their role in rumen biohydrogenation and lipid metabolism, the reader is directed to the recent review by Palmquist et al. (19) .
As a consequence of the extensive hydrolysis and biohydrogenation occurring in the rumen, the FA that reach the small intestine are mainly saturated FFA. Some biohydrogenation intermediates can also escape from the rumen, and two of the major ones are trans-11 18:1 (vaccenic acid) formed from both linoleic and linolenic acid and cis-9,trans-11 CLA formed during the biohydrogenation of linoleic acid (Fig. 1) ; these are discussed in more detail in a following section. However, as analytical techniques have improved, it has become clear that biohydrogenation processes are considerably more complex than first thought because a remarkable range of trans 18:1 and CLA isomers have been identified in rumen outflow [see review by Bauman et al. (16) ]. Thus, in addition to the major pathway involving the formation of cis-9,trans-11 CLA and vaccenic acid as intermediates, there must be many more pathways of biohydrogenation. Furthermore, modifications in diet and rumen environment influence biohydrogenation pathways, thereby causing substantial changes in FA intermediates produced in the rumen.
Milk fat synthesis. Milk fat consists of droplets of TG that are coated with cell membrane. Thus, 96-98% of milk fat is TG with the remainder mainly representing small amounts of phopholipids, cholesterol, and cholesterol esters found in the milk fat globule membrane (20) . The TG comprise over 400 FA, with a large portion of these produced as intermediates during lipid metabolism in the rumen (9) . However, most of these FA are present in trace amounts, and it is generally recognized that the major FA in milk fat include saturated FA from 4:0 to 18:0 plus palmitoleic, oleic, linoleic, and trans-18:1 FA.
The FA that compose milk TG are derived from two sources, de novo synthesis and the uptake of preformed FA (20) . Substrates for de novo synthesis are acetate and β-hydroxybutyrate derived from rumen fiber digestion. They are used by the mammary epithelial cell to synthesize short-and medium-chain FA (4:0 to 14:0) plus a portion of the 16-carbon FA. Mammary uptake of circulating long-chain FA is the other source of the FA in milk. This source provides a portion of the 16-carbon and all of the longer-chain FA, and represents FA absorbed from digestion and mobilized from body fat reserves. Those from the diet are transported as TG in VLDL, and mammary uptake depends on the action of lipoprotein lipase residing in the capillary wall. The long-chain FA from body fat reserves are transported as nonesterified FA (NEFA), and mammary uptake is proportional to plasma concentration. Under typical conditions, on a molar basis, about one-half of the FA in milk are synthesized de novo within the mammary gland. Although plasma TG and NEFA represent less than 3% of total plasma lipids, they contribute the remaining one-half (molar basis) of milk FA. However, this can vary according to physiological state. In particular, the contribution of FA from body reserves can vary from about 5% in a well-fed animal to over 20% of milk FA in early lactation when cows are in a negative energy balance (21) .
OMEGA-3 FA
Background. Milk fat contents of EPA (20:5n-3) and DHA (22:6n-3) are of interest because of their potential benefits to human health. The effects of these omega-3 FA on reducing the risk of cardiovascular disease, type 2 diabetes, hypertension, cancer, and certain disruptive neurological functions and their potential mechanisms of action have been extensively reviewed (22) (23) (24) (25) . In human nutrition, there is an effort to increase consumption of these functional food components due to the low intake of omega-3 and the relationship of the intake of omega-3/omega-6 FA; Western diets typically have an omega-6 to omega-3 ratio of 20-30:1, whereas the ideal ratio is thought to be 4:1 or less (26) . As a consequence, opportunities to enhance omega-3 FA in many foods, including dairy products, are being explored.
EPA and DHA are absent or at a minimal level in traditional dairy cow diets; consequently, they are typically present in very low amounts in ruminant products (<0.1% of total FA). However, fish oils, fish by-products, and marine algae are often available as dairy feedstuffs, and these are rich sources of EPA and DHA. Hence, there is an increasing use of fish oils and fish meal in dairy cattle diets. Despite this, only modest increases in the enrichment of EPA and DHA contents in milk fat have been achieved. For example, EPA and DHA in milk fat before fish oil supplementation averaged less than 0.1% of total FA and after supplementation were only marginally increased to 0.2 to 0.3% of total FA [see review by Chilliard et al. (27) ]. The extent to which dietary supplements of FA enhance their secretion in milk fat is referred to as "transfer efficiency." In general, the literature indicates that the transfer efficiency of EPA and DHA to milk fat is low. A review of several studies showed that transfer efficiencies averaged 2 and 4% for EPA and DHA, respectively (27) , and similar values were observed in more recent studies (Table  1) . Interestingly, the transfer efficiency for docosapentaenoic acid (22:5n-3) appears to be higher than for EPA and DHA (27) ; transfer efficiencies of 20-30% were observed following the supplementation of 250 g/d fish oil (28, 29) .
Transfer efficiencies to milk fat are greater when fish oil is directly administered postruminally or fed in a "rumen-protected" form. McConnell (33) reported average transfer efficiencies of 30 and 25% for EPA and DHA, respectively, when 150 g/d of a fractionated fish oil (~40 g/d each of EPA and DHA) was infused into the abomasum. Similar values were reported during duodenal infusions of fish oil (Table 1) . Rumen-protected formulations of fish oil have produced similar results; transfer efficiencies were 32% for EPA and 18% for DHA during supplementation of a formaldehyde-protected tuna orbital oil supplement in lactating dairy cows (34) . Likewise, rumen-protected marine algae resulted in a transfer efficiency of 17% for EPA (35) . Transfer efficiencies also tend to be greater when the FA are supplied by feeding fish meal (36), compared with dietary treatments in which fish oil has been used; thus, the matrix within which the oil is encased provides a degree of protection from rumen biohydrogenation, similar to that seen when oilseeds are fed.
Limitations in the transfer to milk fat. The basis for the low transfer efficiencies for EPA and DHA into milk fat is an active area of research, and two possibilities have been proposed. One hypothesis suggests the low transfer efficiency is because EPA and DHA are biohydrogenated by rumen bacteria. Support for this comes from comparisons showing that the transfer efficiency is about 10-fold greater when the EPA and DHA are provided in a manner to bypass metabolism in the rumen (Table 1 ). Studies utilizing duodenal or omasal sampling in sheep, steers, and lactating dairy cows during fish oil supplementation have quantified the extent of biohydrogenation as 78-100% for EPA and 74-98% for DHA (28, (37) (38) (39) .
Results from in vitro studies have been less consistent. Gulati et al. (40) and Ashes et al. (41) have suggested that there is little biohydrogenation of EPA and DHA; however, more recent in vitro studies have reported substantial biohydrogenation of these FA (42, 43) . Such discrepancies are likely due to the concentration of fish oil used in different studies. It is known that when the proportion of fish oil increases, the percentage of biohydrogenation declines (40, 42, 43) , which is most likely due to the toxic effects of PUFA to certain rumen bacteria. For example, Gulati et al. (40) reported very little biohydrogenation when greater than 5 mg/mL (fish oil/mL rumen fluid) was incubated in vitro, but biohydrogenation was extensive when less than 1 mg/mL was used. Overall, it would appear that, within the normal range of omega-3 FA supplied in dairy cow diets, EPA and DHA will be extensively biohydrogenated unless suitable technologies can be developed to provide protection from rumen bacteria. The second possibility to explain the low transfer efficiency of EPA and DHA to milk fat may be a result of their partitioning into plasma lipid fractions that are less available to the mammary gland (29, 44, 45) . As discussed earlier, the TG fraction of chylomicrons and VLDL is the form of esterified lipid used most extensively by the mammary gland. Brumby et al. (45) first suggested that EPA and DHA were packaged into lipid classes not readily used by the mammary gland. Recent studies have shown that supplements of EPA and DHA give only marginal enhancements in the TG and FFA lipid classes of plasma compared with the cholesterol ester and phospholipid fractions (29, 44) .
Transfer efficiencies of abomasally infused EPA and DHA (27, 33, 46) are similar to transfer efficiencies for abomasally infused isomers of CLA, which have been reported to have transfer efficiencies ranging from 20 to 32% (47) (48) (49) (50) (51) . Such values are still low compared with transfer efficiencies reported for linoleic and linolenic acid. Although linoleic acid transfer efficiencies have been shown to be variable (10-90%), the majority of low values reported in the literature are when large amounts of linoleic acid were infused in cows in early to peak lactation. The majority of studies in established lactation observed transfer efficiencies in the 40-70% range; similar values have been reported for linolenic acid [see review by Chilliard et al. (46) ]. Overall, these results suggest that preferential packaging of EPA and DHA into plasma cholesterol ester and phospholipid fractions may limit mammary uptake and their use for milk fat synthesis.
Finally, potential limitations on the use of fish oils in ruminant diets to increase the EPA and DHA content of milk must be considered. In some instances, fish oil can cause a shift in rumen biohydrogenation, which leads to a reduction in milk fat synthesis in the mammary gland and the production of milk with a low fat content. Although this may be beneficial in some circumstances [see Griinari and Bauman (52) ], milk production with a low fat content is often detrimental, both financially and for many manufacturing processes (21) . The second possible drawback to enhancing the omega-3 content of milk fat relates to the organoleptic properties of milk. Off-flavors due to FA oxidation are of prime concern because of the shift toward greater unsaturation of the milk fat when fish oils are fed. Although some studies have reported flavor problems in milk when fish oil supplements were fed to dairy cows (53), other investigations have observed no adverse effects on flavor score or peroxide index (54) (55) (56) .
CONJUGATED LINOLEIC ACIDS
Background. The intake of CLA in humans is of interest because of the potential health benefits these FA may confer. The anticarcinogenic activity of CLA has been clearly established with in vitro cell culture systems and in vivo animal models for a wide range of cancer types [see reviews by Banni et al. (57) , Belury (58) , and Ip et al. (59) ] . As biomedical studies with animal models expanded in scope, an impressive range of additional health effects were discovered for CLA, including antidiabetogenic, anti-atherogenic, immunomodulation, anti-obesity, and modulation of bone growth (58) . The predominant source of CLA in human diets is ruminant-derived food products, with dairy products contributing about 75% of the total (60) (61) (62) . CLA is a component of the fat in milk; hence, research has concentrated on increasing the CLA content per unit of fat. Processing has little effect on CLA, so the content in food products is related to the CLA concentration in the starting fat (61) .
The presence of CLA in milk fat was first noted in the 1930s by scientists at the University of Reading, United Kingdom (63,64), with Parodi (65) later identifying cis-9,trans-11 CLA as a milk FA that contained a conjugated double bond pair. Subsequent research established that cis-9,trans-11 CLA was the major CLA isomer in ruminant fat representing about 75 to 90% of the total CLA (61, 66) , and the common name of "rumenic acid" has been proposed for this isomer because of its unique relationship to ruminants (67) . As analytical techniques improved, numerous other isomers of CLA were identified in ruminant fat; these are present at much lower concentrations, and they differ by position (e.g., 7-9, 8-10, 9-11, 10-12, or 11-13) or geometric orientation (cis-trans, trans-cis, cis-cis, and trans-trans) of the double bond pair (Table 2 ). Thus far, the biological effects have been extensively examined for only two of the CLA isomers, cis-9,trans-11 and trans-10,cis-12, and there are clear differences. In the context of dairy products, biomedical studies with animal models have documented the anticarcinogenic and antiatherogenic effects of cis-9,trans-11 CLA (58,59,68). Since cis-9,trans-11 CLA is, by a considerable margin, the most predominant CLA isomer in milk fat, enhancing the CLA content of milk is realistically related only to increases in this isomer. The anti-obesity effects of CLA are due to the trans-10,cis-12 isomer; while this isomer can vary in milk fat, it never represents more than 1 or 2% of total CLA, and food products derived from ruminants are thus unlikely to provide sufficient amounts of this isomer to have biological effects on body fat.
Origin of CLA. The major pathways for rumen biohydrogenation of linoleic and linolenic acid are shown in Figure 2 . Note that cis-9,trans-11 CLA is the first intermediate in the pathway, and it is formed only during the biohydrogenation of linoleic acid. In contrast, vaccenic acid is an intermediate formed from both linoleic and linolenic acid. Vaccenic acid and CLA are both present in ruminant fat, and it was generally assumed they were of rumen origin and represented intermediates that had escaped complete biohydrogenation. However, cis-9,trans-11 CLA is only a transitory intermediate in rumen biohydrogenation, whereas vaccenic acid tends to accumulate. Based on this and other considerations, Griinari and Bauman (69) proposed that endogenous synthesis could be an important source of cis-9,trans-11 CLA in milk fat, with synthesis involving the enzyme ∆9-desaturase and vaccenic acid as the substrate.
The importance of endogenous synthesis of cis-9,trans-11 CLA has been examined in a series of in vivo investigations encompassing a range of diets characteristic of lactating dairy cows [see reviews by Palmquist et al. (19) and Bauman et al. (66) ]. One of the strategies to investigate the importance of endogenous synthesis was a direct inhibition of ∆9-desaturase. For these in vivo studies, sterculic oil isolated from the nuts of Sterculia foetida was used. Sterculic oil contains about 60% sterculic acid [8-(2-octyl-1-cyclopropenyl) octanoic acid], a cyclopropenoic FA that is a potent inhibitor of ∆9-desaturase. Another approach was to compare values of estimated rumen outflow of CLA with the quantity of CLA secreted in milk fat. This indirect method provided an estimate of the maximum proportion of milk fat CLA that could originate from rumen production. Overall, results from these different approaches and investigations were consistent; endogenous synthesis accounted for the majority of the cis-9,trans-11 CLA present in milk fat with over 70 to over 90% originating from the conversion of vaccenic acid catalyzed by ∆9-desaturase (19, 66) .
In 1998, Yurawecz et al. (70) discovered that ruminant fat contained trans-7,cis-9 CLA. This CLA isomer had not been reported previously because it co-elutes with cis-9,trans-11 CLA under typical conditions with GC analysis. The milk fat content of trans-7,cis-9 CLA is generally about 10% of cis-9,trans-11 CLA, making it the second most prevalent CLA isomer. Endogenous synthesis is also the source of this CLA isomer; it is derived by the action of ∆9-desaturase on trans-7 18:1 that is produced in the rumen (71, 72) . In contrast to cis-9,trans-11 and trans-7,cis-9 CLA, other CLA isomers in milk fat appear to be exclusively of rumen origin. There are no specific mammalian desaturases analogous to ∆9-desaturase that could account for their presence. Rather, they are detected in rumen and duodenal contents, and estimates of rumen outflow are sufficient to account for the trace amounts of these CLA isomers secreted in milk fat (28, 72) .
Two of the minor CLA isomers merit further mention, trans-11,cis-13 CLA and trans-10,cis-12 CLA. Kraft et al. (74) recently reported that trans-11,cis-13 CLA was found at concentrations of approximately 8% of the total CLA present in milk fat produced by dairy cattle grazing Alpine regions of Switzerland. The rumen biohydrogenation pathways that produce this CLA isomer and the physiological basis for the relatively greater concentrations in milk fat from cattle grazing Alpine pastures are unknown. The trans-10,cis-12 CLA isomer is of interest because it is often produced in relatively greater quantities in the rumen of cows fed diets associated with milk fat depression. Indeed, this isomer has been shown to be a potent inhibitor of milk fat synthesis [see reviews by Bauman and Griinari (21) and Bauman et al. (66) ].
Altering milk fat content. Diet is the major determinant of milk CLA content, and over the last decade, numerous experiments have been carried out with the objective of enhancing the milk fat content of CLA [see reviews by Chilliard et al. (27, 46) , Bauman et al. (79) , and Stanton et al. (80) ]. The key to increasing milk CLA is to increase rumen vaccenic acid output, allowing for increased endogenous synthesis in the mammary gland. Maximizing rumen output of vaccenic acid can be achieved in two ways: by increasing the supply of 18-carbon PUFA precursors and by inhibiting vaccenic acid reduction to stearic acid. Increasing the dietary supply of 18-carbon PUFA substrates is most easily achieved by the addition of plant oils high in linoleic and/or linolenic acids. The effects of different types and amounts of plant oils have been investigated, and a range of plant oils have been shown to be effective in increasing milk CLA content. The coat of oilseeds offers some protection from rumen biohydrogenation; thus, the use of different oilseeds and processing techniques has also been investigated (81) (82) (83) . Oilseeds high in linoleic and/or linolenic acid, processed so that oil was accessible to biohydrogenating bacteria, resulted in greater increases in milk CLA compared with whole oil seeds, but were not as efficient as using the pure oil. Plant oils are often added to dairy cattle diets as calcium salts of FFA, and a Data are derived from eight studies in which FA analyses were carried out on milk samples (28, (72) (73) (74) (75) (76) , butter (77) , and cheese (78).
Chouinard et al. (82) fed calcium salts of canola (rape), soybean, and linseed oil. All three increased the CLA content of milk fat; however, those containing the greatest amounts of linoleic and linolenic (soybean and linseed, respectively) caused the greatest increases. The lipid content of ruminant diets is generally restricted to less than 7% because higher amounts adversely affect the metabolism of rumen bacteria, thereby impairing rumen fermentation and animal performance (84, 85) . Thus, there is a limit to the extent that one can provide dietary lipid supplements to increase rumen output of vaccenic acid and CLA. Even at a modest level of plant oil supplementation, the rumen environment can be modified so that a portion of the biohydrogenation pathways are shifted to produce trans-10 18:1 and trans-10,cis-12 CLA as intermediates. These dietary situations are associated with milk fat depression, and increasing the CLA content of fat while reducing total milk fat secretion is often unacceptable to producers [see reviews by Bauman and Griinari (21, 86) ].
Dietary factors that affect rumen bacteria involved in biohydrogenation, either directly or indirectly via changes in the rumen environment, can also affect the CLA content of milk fat. These changes typically involve an inhibition of the final biohydrogenation step, which converts vaccenic acid to stearic acid. Several examples have been well characterized including alterations in the forage/concentrate ratio, dietary supplements of fish oil, and restricted feeding (79) . The most effective of these is the use of fish oil, and the general trend is that equivalent amounts of dietary fish oil compared with plant oils result in a greater increase in milk CLA content (28) (29) (30) (87) (88) (89) . Fish oils supply only minimal amounts of 18-carbon PUFA; therefore, the increases are most likely the result of a reduction in the final biohydrogenation step where vaccenic acid is converted to stearic acid (69) . In support, DHA has been shown to promote vaccenic acid accumulation in mixed ruminal cultures when incubated with linoleic acid (90) .
Last, a combination of dietary supply of PUFA and modification of the rumen environment can be especially effective in increasing the CLA content of milk fat. Seasonal effects on milk CLA have been known for some time (91) (92) (93) (94) , and these appear related to this. Fresh pasture results in a two-to threefold increase in the CLA content of milk fat, but the effect diminishes as the pasture matures (81, 92, 93, 95, 96) . These results cannot be totally explained in terms of the FA composition and supply of PUFA that grass provides; therefore, additional factors or components of grass must promote the production of vaccenic acid in the rumen, and these lessen in effect as the pasture matures.
Physiological factors that affect milk fat content of CLA have also been examined, and differences among individuals are particularly striking. Even when diet and other physiological variables are similar, there is still a two-to threefold range among individuals in the milk fat concentration of CLA (93, (97) (98) (99) . A similar level of variation also occurs in the milk fat desaturase index (a proxy for ∆9-desaturase activity), with a several-fold range among cows (93, (97) (98) (99) . These animal differences appear to have a genetic basis, although this has not been examined rigorously. Cows maintain a consistent hierarchy in milk CLA content and desaturase index over time when fed the same diet and when switched between diets (99). The effect of breed (Holstein vs. Brown Swiss) was examined in a large study (>200 cows) by Kelsey et al. (97) , and no differences were observed. Although some have proposed breed differences in the CLA content of milk fat (89, (100) (101) (102) , these studies have often involved very few animals, were confounded by diet, or both. Thus, if breed differences do exist in the CLA content of milk fat and desaturase index, they must be minor compared with the effect of diet and individual animal variations (19, 66) . Differences in milk CLA among cows are presumably related to individual variations in expression of the ∆9-desaturase gene and rumen outflow of vaccenic acid and CLA. Examination of other physiological factors has established that the milk fat content of CLA and desaturase index have little relation to milk or milk fat yield, parity, or stage of lactation (97, 103) .
We have used such feeding regimes and taken advantage of individual animal variation to produce CLA-enriched butter for use in biomedical studies with animal models. Ip et al. (104) first showed that cis-9,trans-11 CLA was a potent anticarcinogen when supplied as a natural food component; dietary consumption of CLA-enriched butter was effective in reducing the incidence of tumors in a rat model of mammary carcinogenesis. We have subsequently shown that vaccenic acid derived from CLA-enriched butter increased tissue content of CLA and reduced mammary tumorogenesis (105) and that the anticarcinogenic effect of vaccenic acid is mediated predominantly, perhaps exclusively, by its conversion to cis-9,trans-11 CLA (106). These findings highlight the fact that vaccenic acid should also be considered as a FA with particular benefits to human health. Given that humans convert approximately 20% of dietary vaccenic acid to cis-9,trans-11 CLA via ∆9-desaturase (107), Parodi (61) has suggested that CLA intake multiplied by 1.4 would provide an estimate of the effective physiological dose of CLA derived from ruminant products.
CLA-enriched dairy products have been evaluated for taste, organoleptic properties, and storage characteristics in comparisons with standard dairy products. Off-flavors due to FA oxidation are of prime concern because of the shift toward greater unsaturation of the milk fat. We recently produced 2% fat milk with high CLA and vaccenic acid (47 and 121 mg/g FA, respectively) and compared this with a standard 2% milk (5 and 14 mg/g FA, respectively). Evaluations of the milk for up to 14 d postpasteurization indicated no differences in sensory and triangle taste tests, or in susceptibility to develop oxidized flavors under both light and dark storage conditions (56) . Similar results have been observed by others, with milk that had a less marked enrichment of CLA (54, 55, (108) (109) (110) .
In summary, there are four areas to consider when designing diets to increase the CLA content of milk fat: (i) increase 18-carbon PUFA precursors in the diet (linoleic and linolenic acids); (ii) maintain normal biohydrogenation pathways (vaccenic acid pathway); (iii) inhibit the final biohydrogenation step (vaccenic acid to 18:0); (iv) increase desaturation of vaccenic acid to cis-9,trans-11 CLA in the mammary gland. Future strategies will thus involve establishing dietary and nutritional conditions that maximize rumen outflow of vaccenic acid and cis-9,trans-11 CLA, optimizing the amount and activity of ∆9-desaturase in mammary tissue, and identifying the genetic basis for the large differences among individuals in CLA-related variables. Obviously, before CLA-enriched foods are widely marketed, studies would need to examine commercial applications and be extended to a wide range of food products.
FUTURE CONSIDERATIONS
Consumers are increasingly aware of "functional food" components that can have positive effects on health maintenance and disease prevention. A number of specific FA are now recognized as having beneficial effects on human health, and these include the omega-3 FA and cis-9,trans-11 CLA that are present in milk fat. Enhancing their content in milk fat requires an understanding of the interrelationship between dietary supply of lipid, rumen fermentation, and mammary synthesis of milk fat. Milk and dairy products normally contain very low amounts of EPA and DHA, and increasing their content is limited primarily because their biohydrogenation in the rumen is extensive and secondarily because they circulate in specific plasma lipid fractions that contribute minimally to the mammary supply of FA. These challenges must be addressed to achieve substantial increases in EPA and DHA levels in milk fat, and the formulation of supplements of EPA and DHA that are protected from metabolism by rumen bacteria has potential to address the biohydrogenation problem.
The predominant source of cis-9,trans-11 CLA in milk fat is endogenous synthesis from vaccenic acid, and thus strategies that center on enhancing rumen output of vaccenic acid and increasing tissue activity of ∆9-desaturase. Diet has a major effect on milk fat content of CLA, and there is also a wide variation among individuals. Through modification of dairy cow diets and selection of cows with the highest milk CLA content, it is possible to produce milk that is significantly enriched with CLA. Vaccenic acid is also present in milk fat, and its contribution to CLA must be considered because it supplies precursor for the endogenous synthesis of CLA in humans. On this basis, vaccenic acid would also be considered as a functional food component in dairy products with potential benefits to human health. Finally, the education of the public that not all FA are equal is required. This is of special importance with the introduction of trans FA labeling of foods as undesirable and the fact that both vaccenic acid and cis-9,trans-11 CLA are trans FA.
